CLINICAL TRIALS PROFILE FOR TIAGABINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for TIAGABINE HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00015132 ↗ | Tiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1999-03-01 | The purpose of this CREST (Clinical Rapid Evaluation Screening Trial) study is the use of tiagabine, sertraline, or donepezil for the treatment of cocaine dependence using a modified placebo-controlled experimental design. |
| NCT00015769 ↗ | Pilot Study of Levetiracetam (Keppra® (Registered Trademark)) for Bipolar Illness | Completed | National Institute of Mental Health (NIMH) | Phase 2 | 2001-04-01 | This study will explore the possible effectiveness of levetiracetam in patients with bipolar illness who have not responded adequately to standard treatments. Levetiracetam was recently approved to treat seizures. Other drugs in the same class as levetiracetam, including carbamazepine and valproate, are widely recognized as substitute medications for lithium or are used as an adjunct to it, and other anticonvulsants have also shown promise in improving bipolar symptoms. Patients with bipolar illness whose manic, depressed or unstable moods are not adequately controlled by their current treatment and who have not responded previously to two standard treatments (i.e., lithium, valproate, carbamazepine or neuroleptics) may be eligible for this study. Participants will take levetiracetam starting at 500 mg daily. If this dose is well tolerated, it will be increased to 500 mg twice a day. Every 3 days, doses may be increased until the target dose of 3000 mg/day is reached. Higher doses, not to exceed 4000 mg/day, may be tried in patients who do not respond fully to the lower doses. Patients and observers will use standard ratings to evaluate the patients' response to therapy during the 8-week study. If, after 8 weeks, the results appear promising, patients may continue treatment for an additional 6 months to evaluate longer-term effects. |
| NCT00068770 ↗ | Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT | Terminated | National Cancer Institute (NCI) | Phase 2 | 2003-10-01 | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme. |
| NCT00068770 ↗ | Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT | Terminated | Sidney Kimmel Comprehensive Cancer Center | Phase 2 | 2003-10-01 | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme. |
| NCT00068770 ↗ | Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | 2003-10-01 | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme. |
| NCT00086255 ↗ | Tiagabine for the Treatment of Cocaine Dependence - 1 | Completed | University of Cincinnati | Phase 2 | 2002-10-01 | The purpose of this study is to assess tiagabine for the treatment of cocaine dependence. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TIAGABINE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for TIAGABINE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for TIAGABINE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for TIAGABINE HYDROCHLORIDE
Sponsor Name
